Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence
of antiphospholipid antibodies (aPL)(lupus anticoagulant, anticardiolipin antibodies and anti …

Therapeutic success in treating patients with systemic lupus erythematosus (SLE) is limited
by the multivariate disease etiology, multi-organ presentation, systemic involvement, and …

Systemic lupus erythematosus (SLE) often features extensive cardiovascular (CV)
comorbidity and patients with SLE are at significantly increased risk of CV event occurrence …

The observations that traditional cardiovascular disease (CVD) risk factors fail to fully
account for the excessive cardiovascular mortality in patients with systemic lupus …

Even though diagnosis and management pathways have been substantially improved over
the last years, autoimmune rheumatic diseases (AIRDs) such as rheumatoid arthritis (RA) …

Objective To identify the different clinical phenotypes of antiphospholipid syndrome (APS) by
using cluster analysis and describe cumulative damage of disease clusters. Methods This …

Vascular disease is a major cause of morbidity and mortality in patients with systemic
autoimmune diseases, particularly systemic lupus erythematosus (SLE). Although comorbid …

Objectives Although dyslipidemia is a strong risk factor for thrombosis in antiphospholipid
syndrome (APS), it has been poorly studied. This study aimed to assess lipids profile and …

Objectives Systemic inflammation is increasingly being recognised as a possible
mechanism for acute arterial thrombotic events, including acute coronary syndrome (ACS) …

Coronary artery disease (CAD) is a leading cause of death in patients with systemic lupus
erythematosus (SLE). Despite clinical evidence supporting an association between SLE and …